一种新型过继性合成TCR与抗原受体(STAR)T细胞疗法用于B细胞急性淋巴细胞白血病
研究开发了基于T细胞受体复合物的合成TCR与抗原受体(STAR),在白血病异种移植小鼠模型中STAR-OX40 T细胞较常规CAR-T细胞显示更优的抗肿瘤活性;18例复发/难治B细胞急性淋巴细胞白血病患者接受STAR-OX40 T细胞输注后4周全部达完全缓解,16/18(88.9%)桥接异基因造血干细胞移植,中位随访545(433-665)天时16例中12例(75%)无白血病生存。
要点
- STAR-OX40 T细胞在动物模型中较常规CAR-T细胞显示更优的肿瘤特异性细胞毒作用。
- 18例复发/难治B-ALL患者输注后4周完全缓解率100%,16/18(88.9%)接受巩固性allo-HSCT。
- 中位随访545(433-665)天,16例移植患者中12例(75%)无白血病生存。
核心结论
- 临床前研究显示STAR-OX40 T细胞较常规CAR-T细胞具有更强的抗肿瘤效力。
- 首次人体临床试验表明STAR-OX40 T细胞耐受性良好,是治疗复发/难治B-ALL的有效治疗平台。
研究设计与样本
- 临床前研究:构建基于T细胞受体复合物的CAR(STAR),含两个蛋白模块,各含抗体轻链或重链可变区与TCR α或β链恒定区融合至OX40共刺激域,用STAR-OX40慢病毒载体转导T细胞,并采用白血病异种移植小鼠模型评估抗肿瘤活性。
- I期临床试验(NCT03953599):纳入18例复发/难治B细胞急性淋巴细胞白血病患者。
主要发现
- 在异种移植小鼠模型中,STAR-T细胞较常规CAR-T细胞表现出更优的肿瘤特异性细胞毒作用。
- 将OX40整合入STAR进一步改善了肿瘤靶向T细胞的增殖和持久性。
- 临床试验中,STAR-OX40 T细胞输注后4周100%患者达完全缓解,16/18(88.9%)患者接受巩固性异基因造血干细胞移植。
- 中位随访545(433-665)天,16例接受移植患者中12例(75%)保持无白血病生存。
- 2例未接受巩固性异基因造血干细胞移植的患者分别在第58天和第186天复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We developed a T-cell-receptor (TCR) complex-based chimeric antigen receptor (CAR) named Synthetic TCR and Antigen Receptor (STAR). Here, we report pre-clinical and phase I clinical trial data (NCT03953599) of this T-cell therapy for refractory and relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) patients. STAR consists of two protein modules each containing an antibody light or heavy chain variable region and TCR α or β chain constant region fused to the co-stimulatory domain of OX40. T-cells were transduced with a STAR-OX40 lentiviral vector. A leukemia xenograft mouse model was used to assess the STAR/STAR-OX40 T cell antitumor activity. Eighteen patients with R/R B-ALL were enrolled into the clinical trial. In a xenograft mouse model, STAR-T-cells exhibited superior tumor-specific cytotoxicity compared with conventional CAR-T cells. Incorporating OX40 into STAR further improved the proliferation and persistence of tumor-targeting T-cells. In our clinical trial, 100% of patients achieved complete remission 4 weeks post-STAR-OX40 T-cell infusion and 16/18 (88.9%) patients pursued consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twelve of 16 patients (75%) remained leukemia-free after a median follow-up of 545 (433-665) days. The two patients without consolidative allo-HSCT relapsed on Day 58 and Day 186. Mild cytokine release syndrome occurred in 10/18 (55.6%) patients, and 2 patients experienced grade III neurotoxicity. Our preclinical studies demonstrate super anti-tumor potency of STAR-OX40 T-cells compared with conventional CAR-T cells. The first-in-human clinical trial shows that STAR-OX40 T-cells are tolerable and an effective therapeutic platform for treating R/R B-ALL.
引用
- Wang J, Zhang X, Zhou Z, et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022. PMID: 35491511. doi:10.1002/ajh.26586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。